Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 12, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO) ("Klotho" or the "Company") today announces that it changed its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open today, Thursday, March 12, 2026.

Transaction delivers shareholders direct ownership in one of the largest undeveloped palladium-gold deposits on Earth, establishing a new western champion in critical mineral supply security; Company to rebrand as Greenland Mines CHARLOTTE, N.C. and NUUK, Greenland, March 4, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO) ("Klotho" or the "Company") today announces the acquisition of Greenland Mines Corp. ("Greenland Mines" or "GMC"), a privately held Delaware corporation that controls an 80% interest in, and an option to acquire the remaining 20% of, the Skaergaard Project in Southeast Greenland — one of the largest and most significant undeveloped palladium, gold, and platinum deposits in the world.

The Company enlists industry veteran Dr. Bret Barnes to oversee the development of new diagnostic offerings NEW YORK, Feb. 24, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the Company) announces the development of two genomics-based diagnostic tests that will be utilized in Klotho's clinical trials and to be provided as a service in the field of longevity and the understanding of the relationships between biological age and chronologic age.   One genomics test being developed is a quantitative DNA methylation assay that determines the extent of DNA methylation of the anti-aging gene called alpha-Klotho using cell-free DNA isolated through a blood draw as a validated marker of biologic aging.

NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO) ("Klotho" or the Company) announces the acceptance of 18 claims within a patent application filed in Australia for composition and use of human secreted Klotho protein ("s-KL") isoform of the human gene sequence. The Australian government entity IP Australia has notified the Company and the licensor of the technology, Universitat Autonoma de Barcelona, that these claims are to be granted.

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho", or "the Company"), a U.S.-based biogenetics company, announces that CEO Dr. Joseph Sinkule will be presenting at the 2026 Biotech Showcase in San Francisco on January 13, 2026 at 11:30AM PT.  The Biotech Showcase is to be held January 12-14, 2026 at the Hilton San Francisco Union Square.

NEW YORK , Nov. 7, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO ) (the "Company" or "Klotho"), a U.S.-based biogenetics company, announces it has been selected as winner of the Fifth Annual BioTech Breakthrough Award in the "Cell Therapy Innovation of the Year" category. Klotho Neurosciences earned this recognition for its pioneering work developing transformative gene and cell therapies using a patented, secreted form of the human Klotho gene (s-KL) to address devastating neurodegenerative and age-related diseases, including ALS, Alzheimer's disease, and Parkinson's disease.

NEW YORK , Aug. 12, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy candidate using the AAVnerGene Inc. (AAVnerGene) platform technology. As previously announced, AAVnerGene is an innovation-driven biotech renowned for its transformative technologies in adeno-associated viruses (AAV) manufacturing and tissue-targeted delivery.